Oxandrolone 2.5mg tablets
Requires a prescription from a doctor or prescriber
A synthetic hormone with anabolic and androgenic properties.
Minimal controls; includes benzodiazepines and anabolic steroids
Legal requirements and restrictions
Anabolic steroids and related substances. Possession for personal use is not an offence, but supply is controlled.
Legal requirements
- Prescriptions valid for 28 days
- No controlled drugs register required
- No safe custody requirements
- Import/export restrictions apply
Other medicines in this category
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Oxandrolone
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Oxandrolone
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 20 · Randomised trials: 7 · 1996–2026
Showing the 50 most relevant studies, sorted by most relevant.
Jiaqi Lou, Ziyi Xiang, Xiaoyu Zhu, et al.
Frontiers in Medicine, 2025
Izabelle de Mello Gindri, G. Almeida, Caio Saraiva, et al.
Endocrine and Metabolic Science, 2025
L. Câmara, M. Starling, E. Suzigan
Journal of Pharmaceutical Research International, 2023
Andrine Lisley de Azevedo Martins, Douglas José Angel
Revista ft, 2026
This literature review article sought to investigate the therapeutic use of oxandrolone, a steroid widely used for its anabolic properties, mainly to increase the performance of athletes. Its clinical use in the treatment of various pathological conditions, on the other hand, is not well known. Thus, the objective of this work is to synthesize information, from the existing literature, regarding oxandrolone aimed at clinical use. For this, a literature review was carried out, based on a search for articles in Science Direct and in the PUBMED databases, considering clinical studies and systematic reviews, published between 2019 and 2024. The literature showed that the main use of oxandrolone is indicated for height gain in syndromes such as Klinefelter and Turner, in the treatment of patients with severe burns, critically ill patients and even in the treatment of blood disorders due to bone marrow disorders. Its therapeutic properties are based mainly on its hematogenic, anabolic and immunomodulatory properties, which aid in the recovery of hematologic dyscrasias, loss of muscle mass and healing, respectively. The literature also shows that the use of oxandrolone is safe, with lower cardiovascular and hepatotoxic risks compared to other steroids. The main adverse effects include virilization, acne and deepening of the voice. However, these are transient effects.
Abstract licence: CC BY 4.0
R. A. Alzahrani, Ibrahim R Halawani, S. M. Alghamdi, et al.
European Journal of Plastic Surgery, 2025
J. Ring, M. Heinelt, Shubham Sharma, et al.
Journal of burn care & research : official publication of the American Burn Association, 2019
Laura J. Porro, D. Herndon, N. Rodriguez, et al.
Journal of the American College of Surgeons, 2012
S. Davis, Matthew Cox-Martin, M. Bardsley, et al.
The Journal of Clinical Endocrinology & Metabolism, 2016
Nicole Sheanon, P. Backeljauw
International Journal of Pediatric Endocrinology, 2015
D. Hart, S. Wolf, P. Ramzy, et al.
Annals of Surgery, 2001
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
0.55 hours
Mechanism
Oxandrolones interact with androgen receptors in target tissues.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
0.55 hours
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 369 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:19022849
Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation .
PMID:20812024
Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC A14AA08
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Oxandrolone
Additional database identifiers
ChemSpider
5667
ZINC
ZINC000003813047
HUGO Gene Nomenclature Committee (HGNC)
HGNC:644
GenAtlas
AR
GeneCards
AR
GenBank Gene Database
M20132
GenBank Protein Database
178628
Guide to Pharmacology
628
UniProt Accession
ANDR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72